Evidence map›Paper›PMID 40719750›Full record

ArticleCancer medicine2025

Early Acute Kidney Injury and Its Association With Survival in Patients With Metastatic Non-Small-Cell Lung Cancer Treated With Front-Line Immunotherapy-Based Therapies.

Mingjia Li, Po-Lan Su, Songzhu Zhao, Grace Cheng, Nicholas Jones, Kenneth Chian, Natalie Johns, Adam Khorasanchi, Adeoluwa Adeluola, Annastasia Petouhoff and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Mingjia LiDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.ORCID https://orcid.org/0000-0002-3910-4179
Po-Lan SuDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Songzhu ZhaoDepartment of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, USA.
Grace ChengDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Nicholas JonesDivision of Hospital Medicine, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Kenneth ChianCollege of Medicine, The Ohio State University, Columbus, USA.
Natalie JohnsCollege of Medicine, The Ohio State University, Columbus, USA.
Adam KhorasanchiDivision of Hospital Medicine, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Adeoluwa AdeluolaCollege of Pharmacy, The Ohio State University, Columbus, USA.
Annastasia PetouhoffDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Daniel J SpakowiczDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.ORCID https://orcid.org/0000-0003-2314-6435
Lai WeiDepartment of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, USA.
Xiaoying WangDepartment of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, USA.
Christopher CossCollege of Pharmacy, The Ohio State University, Columbus, USA.
Mitch A PhelpsCollege of Pharmacy, The Ohio State University, Columbus, USA.
Lingbin MengDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Yuanquan YangDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Alexa MearaDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Mohamed I ElsaidDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.ORCID https://orcid.org/0000-0001-7963-2438
Jinesh GheeyaDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Logan RoofDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.ORCID https://orcid.org/0000-0002-9362-7851
Asrar AlahmadiDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Regan M MemmottDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Jacob KaufmanDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Kai HeDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Carolyn J PresleyDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.ORCID https://orcid.org/0000-0002-2607-5639
Peter G ShieldsDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
David P CarboneDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Gregory A OttersonDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Jason ProsekDivision of Nephrology, Department of Internal Medicine, The Ohio State University, Columbus, USA.
Dwight H OwenDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, USA.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9M
The Chesapeake-Ohio Pharmacokinetics Core for The ETCTNU24CA247648 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Mitch A Phelps · 2020 to 2026
$3.6M
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung CancerR01CA273924 · NCI · OHIO STATE UNIVERSITY · PI COSS, CHRISTOPHER C., MACE, THOMAS A · 2022 to 2025
$3.1M
NCATS NIH HHS UL1 TR002733NCATS NIH HHS UL1TR002733NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA273924NCI NIH HHS U24 CA247648NIH HHS P30CA016058NIH HHS R01CA273924REDCap project
6 · The paper itself

Abstract

introductionImmune checkpoint inhibitors (ICIs) have revolutionized metastatic NSCLC treatment. Acute kidney injury (AKI) is a common complication of ICI-based therapies, alone or with chemotherapy. This study investigates the association between early AKI and 12-month survival among patients with metastatic NSCLC receiving front-line ICI-based treatment.

methodsThis retrospective study included metastatic NSCLC patients who received ICI-based therapy (2017-2022). Early AKI was defined as a creatinine increase ≥ 1.5 times baseline within 21 days of the fourth cycle or last cycle if fewer than four were given. Clinical characteristics were compared using t-tests and chi-squared tests. Survival differences were assessed by Kaplan-Meier and log-rank tests, with Cox models evaluating the association between AKI and 12-month survival.

resultsOf the 310 patients, AKI occurred in 38 patients (12.6%), with 8 patients (2.3%) missing follow-up creatinine data. The hazard ratio (HR) for death within 12 months for patients who developed early AKI was 1.733 (95% CI 1.060-2.835, p = 0.026). The highest rate of early AKI was seen in patients receiving pemetrexed, pembrolizumab, and carboplatin (16.7%), compared to 11.1% for pembrolizumab monotherapy and 4.5% for pembrolizumab with paclitaxel and carboplatin. Although patients who recovered renal function were more likely to continue immunotherapy, 12-month survival rates did not significantly differ (52.2% vs. 46.7%).

conclusionsEarly AKI during pembrolizumab-based treatment in metastatic NSCLC patients was associated with reduced 12-month survival. These findings highlight the need for close monitoring and preventive strategies to manage AKI in this population.

Indexed as

Acute Kidney InjuryAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesImmune Checkpoint Inhibitorsacute renal failureimmune checkpoint inhibitorsimmunotherapynon‐small‐cell lung cancerpembrolizumabsurvival

Identifiers

PMID40719750
PMCPMC12302575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.